MEDIA FEATURES

Dr Dionysis Papadatos Pastos, London Oncologist: Media

Dr Papadatos-Pastos Featured in Healthcare in London

Dr Dionysis Papadatos-Pastos was featured in the seventh edition of Healthcare in London, highlighting the benefits of receiving cancer treatment in London through a collaborative, specialist-led approach. The article showcases the multidisciplinary team treating lung cancer, mesothelioma, and thymic tumours using advanced systemic therapies and local treatments for oligometastatic disease.

AS SEEN IN

"New Year New You" distributed with The Guardian 4th January 2025

Better recovery for lung cancer 2025. Recent advances in lung cancer treatment are bringing new hope to patients, with exciting developments in immunotherapy, targeted therapies, and antibody-drug conjugates (ADCs). Immunotherapy harnesses the body’s immune system to recognise and fight cancer cells, offering a less invasive alternative to traditional chemotherapy.

Dr Papadatos-Pastos in the Evening Standard (10 September 2024)

Hopeful horizons for lung cancer patients. Lung cancer treatment has made great strides in recent years, offering patients more effective options and better outcomes. Traditional treatments like surgery, chemotherapy and radiation are still used, but newer approaches are making a big difference.

AS SEEN IN

Dr. Papadatos-Pastos featured in The GUARDIAN – March 8, 2025, Underscoring the Importance of Early Detection for Lung Cancer and Expert Care

Prioritise early lung cancer detection and expert care. Recognising and investigating symptoms that may indicate lung cancer — such as a persistent cough, worsening shortness of breath, haemoptysis (coughing up blood) and unexplained weight loss — is crucial.

AS SEEN IN

CONFERENCE HIGHLIGHTS

Dr Papadatos-Pastos at the Royal Society of Medicine

Dr. Papadatos-Pastos was invited to speak at the Royal Society of Medicine on the vital role of next-generation sequencing (NGS) in the treatment of non-small cell lung cancer (NSCLC). His talk focused on how to effectively integrate advances in molecular profiling into routine clinical practice, while also addressing current challenges and limitations in implementation. He emphasised the transformative impact of our growing understanding of cancer biology—particularly when combined with novel therapies—on the treatment landscape of lung cancer.

Dr Papadatos-Pastos at the 5th International Meeting on Lung Cancer

The 5th International Meeting on Lung Cancer was a highly successful event, bringing together leading experts and clinicians to discuss the latest advancements in lung cancer treatment. Dr. Papadatos-Pastos, serving as a member of both the organizing and scientific committees, played a crucial role in shaping the program, which featured distinguished speakers from the US, UK, and across Europe. This gathering fostered collaboration and knowledge-sharing, as experts presented insights into cutting-edge therapies, including immunotherapy and targeted treatments, and discussed their impact on patient outcomes. The meeting underscored the importance of international cooperation in advancing lung cancer care and improving survival rates.

Dr. Papadatos-Pastos presented the latest data on MET-targeted therapies in NSCLC alongside a distinguished faculty at the 2025 British Thoracic Oncology Group (BTOG) Meeting in Belfast

As a dedicated oncologist specializing in non-small cell lung cancer (NSCLC), I have developed a particular expertise in the management of MET-driven disease, including patients harboring MET exon 14 (METex14) skipping mutations. With the emergence of MET-targeted therapies such as capmatinib and tepotinib, optimizing patient outcomes requires not only precision medicine but also a deep understanding of treatment-related toxicities and how to mitigate them effectively.

Dr Papadatos-Pastos at 1st Cyprus Oncology Conference in Nicosia, Cyprus

New Hope for Oligometastatic Non-Small Cell Lung Cancer: Breakthrough Treatments in 2025 Bringing Patients Closer to Long-Term Survival. At the 1st Cyprus Oncology Conference in Nicosia, Dr. Papadatos-Pastos delivered a compelling presentation on the role of systemic therapies in optimizing treatment outcomes for oligometastatic non-small cell lung cancer (NSCLC). He highlighted the importance of chemotherapy, along with the latest advancements in targeted therapies and immunotherapy, emphasizing their role in enhancing long-term disease control.

ADVANCING KNOWLEDGE THROUGH COLLABORATION

Each media feature and conference participation represents Dr Papadatos-Pastos’s dedication to continuous learning and sharing knowledge with peers worldwide. His work combines cutting-edge research with compassionate care, ensuring that every patient benefits from the latest scientific advances in thoracic oncology.